TY - JOUR
T1 - A literature review of quality assessment and applicability to HTA of risk prediction models of coronary heart disease in patients with diabetes
AU - Jiu, Li
AU - Wang, Junfeng
AU - Somolinos-Simón, Francisco Javier
AU - Tapia-Galisteo, Jose
AU - García-Sáez, Gema
AU - Hernando, Mariaelena
AU - Li, Xinyu
AU - Vreman, Rick A.
AU - Mantel-Teeuwisse, Aukje K.
AU - Goettsch, Wim G.
PY - 2024/3
Y1 - 2024/3
N2 - This literature review had two objectives: to identify models for predicting the risk of coronary heart diseases in patients with diabetes (DM); and to assess model quality in terms of risk of bias (RoB) and applicability for the purpose of health technology assessment (HTA). We undertook a targeted review of journal articles published in English, Dutch, Chinese, or Spanish in 5 databases from 1st January 2016 to 18th December 2022, and searched three systematic reviews for the models published after 2012. We used PROBAST (Prediction model Risk Of Bias Assessment Tool) to assess RoB, and used findings from Betts et al. 2019, which summarized recommendations and criticisms of HTA agencies on cardiovascular risk prediction models, to assess model applicability for the purpose of HTA. As a result, 71 % and 67 % models reporting C-index showed good discrimination abilities (C-index >= 0.7). Of the 26 model studies and 30 models identified, only one model study showed low RoB in all domains, and no model was fully applicable for HTA. Since the major cause of high RoB was inappropriate use of analysis method, we advised clinicians to carefully examine the model performance declared by model developers, and to trust a model if all PROBAST domains except analysis showed low RoB and at least one validation study conducted in the same setting (e.g. country) was available. Moreover, since general model applicability is not informative for HTA, novel adapted tools may need to be developed.
AB - This literature review had two objectives: to identify models for predicting the risk of coronary heart diseases in patients with diabetes (DM); and to assess model quality in terms of risk of bias (RoB) and applicability for the purpose of health technology assessment (HTA). We undertook a targeted review of journal articles published in English, Dutch, Chinese, or Spanish in 5 databases from 1st January 2016 to 18th December 2022, and searched three systematic reviews for the models published after 2012. We used PROBAST (Prediction model Risk Of Bias Assessment Tool) to assess RoB, and used findings from Betts et al. 2019, which summarized recommendations and criticisms of HTA agencies on cardiovascular risk prediction models, to assess model applicability for the purpose of HTA. As a result, 71 % and 67 % models reporting C-index showed good discrimination abilities (C-index >= 0.7). Of the 26 model studies and 30 models identified, only one model study showed low RoB in all domains, and no model was fully applicable for HTA. Since the major cause of high RoB was inappropriate use of analysis method, we advised clinicians to carefully examine the model performance declared by model developers, and to trust a model if all PROBAST domains except analysis showed low RoB and at least one validation study conducted in the same setting (e.g. country) was available. Moreover, since general model applicability is not informative for HTA, novel adapted tools may need to be developed.
U2 - 10.1016/j.diabres.2024.111574
DO - 10.1016/j.diabres.2024.111574
M3 - Article
SN - 0168-8227
VL - 209
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
M1 - 111574
ER -